Galapagos Genomics
From Wikipedia, the free encyclopedia
Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. The Company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.
Onno van de Stolpe is the CEO of the company.
[edit] See also
[edit] Source
- Galapagos Genomics gaat zelf medicijnen ontwikkelen (Dutch)
- Een rotsvast geloof in de Vlaamse biotech
[edit] External links
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
